Abstract
We studied epidermal growth factor receptor (EGFR) expression profile with the aim of an individualized therapy for patients with non-small cell lung cancer (NSCLC) from whom tumor materials are not sufficient for molecular investigations. Using immunohistochemistry, we found a markedly increased EGFR expression with significant difference in term of intensity and distribution from normal mucosa to primary tumors (p < 0.05). Furthermore, patients with EGFR positive tumors had significantly shorter survival than those with EGFR negative tumors (p = 0.0001). Thus, EGFR over-expression is a valuable prognostic marker to predict poor outcome in Tunisian patients with NSCLC.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / diagnosis*
-
Adenocarcinoma / genetics
-
Adenocarcinoma / mortality
-
Adenocarcinoma / pathology
-
Adenocarcinoma of Lung
-
Aged
-
Biomarkers, Tumor / genetics*
-
Carcinoma, Non-Small-Cell Lung / diagnosis*
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Carcinoma, Non-Small-Cell Lung / pathology
-
ErbB Receptors / genetics*
-
Female
-
Gene Expression
-
Humans
-
Immunohistochemistry
-
Lung Neoplasms / diagnosis*
-
Lung Neoplasms / genetics
-
Lung Neoplasms / mortality
-
Lung Neoplasms / pathology
-
Male
-
Middle Aged
-
Neoplasm Staging
-
Predictive Value of Tests
-
Prognosis
-
Research Design
-
Respiratory Mucosa / metabolism*
-
Respiratory Mucosa / pathology
-
Survival Analysis
Substances
-
Biomarkers, Tumor
-
EGFR protein, human
-
ErbB Receptors